ImmunoPrecise Antibodies Ltd. reported earnings results for the second quarter and six months ended October 31, 2023. For the second quarter, the company reported sales was CAD 6.15 million compared to CAD 5.18 million a year ago. Net loss was CAD 2.62 million compared to CAD 7.35 million a year ago. Basic loss per share from continuing operations was CAD 0.1 compared to CAD 0.3 a year ago.
For the six months, sales was CAD 11.84 million compared to CAD 9.87 million a year ago. Net loss was CAD 6.19 million compared to CAD 16.73 million a year ago. Basic loss per share from continuing operations was CAD 0.25 compared to CAD 0.67 a year ago.